INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE STUDY LIBRARY

Narrative review / 2023

A review outlines therapeutic milestones in obesity management, including leptin, melanocortin agonists, incretins, and metabolic surgery.

This review summarizes scientific milestones and therapies developed to address obesity and its cardiometabolic comorbidities. It highlights key developments starting from the discovery of leptin, melanocortin receptor agonists for syndromic obesity, incretin therapies including GLP-1 analogs and unimolecular combinations, and metabolic and bariatric surgery. The authors emphasize that this expanding therapeutic armamentarium warrants a coordinated multidisciplinary approach, such as cardiometabolic expertise centers, to address obesity and its complications.

Study type
Narrative review
Who was studied
Individuals with obesity
What was measured
Pathogenesis and therapeutic developments for obesity and comorbidities

THE PAPER

Milestones in the journey towards addressing obesity; Past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery.

Kokkorakis M, Katsarou A, Katsiki N, Mantzoros CS. Metabolism, 2023.

PubMed 37689110 ↗DOI 10.1016/j.metabol.2023.155689 ↗

Heart & arteriesWeight & appetite

This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.